GT
DAWN

Glenmede Trust’s Day One Biopharmaceuticals DAWN Stock Holding History

Glenmede Trust’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,209
Closed -$203K – 1291
2023
Q2 		$203K Hold
15,209
– – ﹤0.01% 1098
2023
Q1 		$203K Buy
+15,209
New +$297K ﹤0.01% 1103

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

Glenmede Trust's DAWN Position: Q3 2023 in Review

Glenmede Trust sold out of Day One Biopharmaceuticals (DAWN) in Q3 2023, closing a stake of 15,209 shares — an estimated $203K sold.

Glenmede Trust first reported a position in DAWN in Q1 2023 and held it in 2 quarters. The position peaked at $203K in Q2 2023. 130 funds tracked by Wall St. Rank hold DAWN as of Q3 2023.

  • Glenmede Trust reported no remaining Day One Biopharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Glenmede Trust sold 15,209 Day One Biopharmaceuticals shares in Q3 2023, an estimated $203K.
  • Glenmede Trust first reported a position in Day One Biopharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Glenmede Trust's Day One Biopharmaceuticals position peaked at $203K in Q2 2023.
  • 130 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2023.

Based on Glenmede Trust's 13F filing for Q3 2023, filed 14 Nov 2023.